230 related articles for article (PubMed ID: 28367698)
1. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.
Jakeman B; Nasiri M; Ruth L; Morse C; Mahatme S; Patel N
Ann Pharmacother; 2017 May; 51(5):365-372. PubMed ID: 28367698
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
[TBL] [Abstract][Full Text] [Related]
4. Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.
Sangiovanni RJ; Jakeman B; Nasiri M; Ruth L; Mahatme S; Patel N
AIDS Res Hum Retroviruses; 2019 May; 35(5):430-433. PubMed ID: 30612438
[TBL] [Abstract][Full Text] [Related]
5. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
6. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
7. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
8. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
9. Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients.
Ahmed A; Schriever C; Britt N; Yager J; Amin R; McGuey L; Patel N
Ann Hepatol; 2019; 18(4):601-606. PubMed ID: 31078440
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
11. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
Miller CD; El-Kholi R; Faragon JJ; Lodise TP
Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
[TBL] [Abstract][Full Text] [Related]
14. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
16. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
18. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
[TBL] [Abstract][Full Text] [Related]
19. Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance.
Clutter DS; Fessel WJ; Rhee SY; Hurley LB; Klein DB; Ioannidis JP; Silverberg MJ; Shafer RW
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):171-6. PubMed ID: 26855248
[TBL] [Abstract][Full Text] [Related]
20. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
